Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 1/20 | 0.69 |
| ▸ | ESR1 | P03372 | 12/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | CYP27A1 | Q02318 | 2/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4857748 | 0.86 | PRNP (0.53) | PRNPESR1ESR2SMN1; SMN2MPO | |
| SCHEMBL4850670 | 0.83 | ESR2 (0.82) | ESR1ESR2 | |
| SCHEMBL4858819 | 0.83 | ESR2 (0.62) | PRNPESR1ESR2 | |
| SCHEMBL2417960 | 0.80 | ESR2 (0.73) | PRNPESR1ESR2 | |
| SCHEMBL4853566 | 0.79 | ESR2 (0.57) | PRNPESR1ESR2 | |
| SCHEMBL4852297 | 0.76 | ESR2 (0.59) | PRNPESR1ESR2SMN1; SMN2MPO | |
| SCHEMBL5582320 | 0.75 | ESR1 (0.59) | PRNPESR1ESR2 | |
| SCHEMBL2417699 | 0.74 | PRNP (0.81) | PRNPESR1ESR2SMN1; SMN2CYP27A1 | |
| SCHEMBL4856461 | 0.74 | ESR2 (0.83) | ESR1ESR2 | |
| SCHEMBL4850382 | 0.72 | ESR2 (0.83) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060041003-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041003-A1 | Estrogen receptor modulators | GPER1, ESR2, ESR1 | PRNP 1632/4885ESR1 3/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.